Adaptive Biotechnologies Corporation (ADPT) NASDAQ
13.84
-0.3657(-2.57%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
13.84
-0.3657(-2.57%)
Currency In USD
| Previous Close | 14.21 |
| Open | 14.14 |
| Day High | 14.3 |
| Day Low | 13.77 |
| 52-Week High | 20.76 |
| 52-Week Low | 7.16 |
| Volume | 163,318.62 |
| Average Volume | 1.96M |
| Market Cap | 2.13B |
| PE | -35.5 |
| EPS | -0.39 |
| Moving Average 50 Days | 14.49 |
| Moving Average 200 Days | 14.85 |
| Change | -0.37 |
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
GlobeNewswire Inc.
Jan 22, 2026 9:05 PM GMT
SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results
GlobeNewswire Inc.
Jan 12, 2026 12:30 PM GMT
Full year MRD revenue growth of 46% driven by clonoSEQ® testing volumeSEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of th
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 30, 2025 9:05 PM GMT
SEATTLE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat